These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16599651)

  • 21. An evaluation of intrathecal ziconotide for the treatment of chronic pain.
    Jain KK
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2403-10. PubMed ID: 11060815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
    Wermeling DP
    Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrathecal ziconotide for neuropathic pain: a review.
    Rauck RL; Wallace MS; Burton AW; Kapural L; North JM
    Pain Pract; 2009; 9(5):327-37. PubMed ID: 19682321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment challenges and complications with ziconotide monotherapy in established pump patients.
    Thompson JC; Dunbar E; Laye RR
    Pain Physician; 2006 Apr; 9(2):147-52. PubMed ID: 16703976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up.
    Hayek SM; Hanes MC; Wang C; Veizi IE
    Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    Rauck RL; Wallace MS; Leong MS; Minehart M; Webster LR; Charapata SG; Abraham JE; Buffington DE; Ellis D; Kartzinel R;
    J Pain Symptom Manage; 2006 May; 31(5):393-406. PubMed ID: 16716870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain.
    Staquet H; Dupoiron D; Nader E; Menei P
    Pain Physician; 2016 Jul; 19(6):E905-15. PubMed ID: 27454282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziconotide: a new option for refractory pain.
    Prommer E
    Drugs Today (Barc); 2006 Jun; 42(6):369-78. PubMed ID: 16845440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
    Miljanich GP
    Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ziconotide combination intrathecal therapy: rationale and evidence.
    Wallace MS; Rauck RL; Deer T
    Clin J Pain; 2010 Sep; 26(7):635-44. PubMed ID: 20639730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.